IVA337

Phase 3Small molecule

IInventiva Pharma

IVA337 is one of 113 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

FibrosisActive, not recruiting

Systemic SclerosisActive, not recruiting

NASH - Nonalcoholic SteatohepatitisActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

FibrosisPhase 3

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

NASH - Nonalcoholic SteatohepatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

IVA337

IInventiva Pharma

Phase 3

1 2

Tanzeum

GSK

Preclinical

10 3

Insulin 320

Novo Nordisk

Preclinical

43 4

Adenocard

Astellas

Preclinical

1 5

Dostinex

Golytely

Myrbetriq

Lantus

6 9

Lixisenatide

Sanofi

Preclinical

4 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

NCT04849728

Clinical

Trials by Indication[1]

Systemic Sclerosis1 trial

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Completed·IInventiva Pharma·Phase 2·NCT02503644·145 enrolled

Phase 21 trial

Phase 2b Study in NASH to Assess IVA337

Completed·IInventiva Pharma·Phase 2·NCT03008070·247 enrolled

Type 2 Diabetes Mellitus1 trial

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Completed·IInventiva Pharma·Phase 2·NCT05232071·42 enrolled

NASH - Nonalcoholic Steatohepatitis1 trial

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3

Active, not recruiting·IInventiva Pharma·Phase 3·NCT04849728·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for IVA337. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IVA337 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IVA337. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inventiva Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInventiva Pharma

IVA337

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Systemic Sclerosis1 trial

Phase 21 trial

Type 2 Diabetes Mellitus1 trial

NASH - Nonalcoholic Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News